MAPT and Alzheimer disease: Variability in tau PET cut-points inevitably leads to variability in tau positivity rates, which impacts subsequent staging efforts based on biomarker positivities and possible inclusion in clinical treatment trials, as well as increasing estimation uncertainty which hinders reproducibility in AD biomarker research.